Compare NMRA & TG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NMRA | TG |
|---|---|---|
| Founded | 2019 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Metal Fabrications |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 302.0M | 239.6M |
| IPO Year | 2023 | 1994 |
| Metric | NMRA | TG |
|---|---|---|
| Price | $0.67 | $7.07 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $7.50 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 136.5K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 5.23 | ★ 151.06 |
| EPS | N/A | ★ 0.34 |
| Revenue | N/A | ★ $800,821,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $20.74 |
| Revenue Growth | N/A | ★ 8.29 |
| 52 Week Low | $0.68 | $6.25 |
| 52 Week High | $3.65 | $10.53 |
| Indicator | NMRA | TG |
|---|---|---|
| Relative Strength Index (RSI) | 21.97 | 42.10 |
| Support Level | N/A | $6.42 |
| Resistance Level | $1.74 | $8.10 |
| Average True Range (ATR) | 0.10 | 0.24 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 6.33 | 46.18 |
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
Tredegar Corp is engaged in the manufacture of aluminum extrusions and polyethylene and polypropylene plastic films. It produces surface protection films, packaging films and films for other markets. The company continues to have two reportable segments: Aluminum Extrusions and High Performance Films. The majority of the revenue is derived form the Aluminum Extrusions segment which produces high-quality, soft and medium strength alloyed aluminum extrusions, custom fabricated and finished, for the building and construction, automotive and transportation, consumer durables goods, machinery and equipment, electrical and renewable energy, and distribution markets.